Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) with or without BCL2 and/or BCL6 rearrangements. We conducted a multicenter retrospective study of MYC-R LS-ABCL...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Torka, Pallawi, Kothari, Shalin K., Sundaram, Suchitra, Li, Shaoying, Medeiros, L. Jeffrey, Ayers, Emily C., Landsburg, Daniel J., Bond, David A., Maddocks, Kami J., Giri, Anshu, Hess, Brian, Pham, Luu Q., Advani, Ranjana, Liu, Yang, Barta, Stefan Klaus, Vose, Julie M., Churnetski, Michael C., Cohen, Jonathon B., Burkart, Madelyn, Karmali, Reem, Zurko, Joanna, Mehta, Amitkumar, Olszewski, Adam J., Lee, Sarah, Hill, Brian T., Burns, Timothy F., Lansigan, Frederick, Rabinovich, Emma, Peace, David, Groman, Adrienne, Attwood, Kristopher, Hernandez-Ilizaliturri, Francisco J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988401/
https://ncbi.nlm.nih.gov/pubmed/31945157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000875
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller